Cargando…

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients

INTRODUCTION: One of the remaining barriers to reaching WHO elimination targets of achieving global hepatitis C (HCV) cure is a lack of an established lower limit of detection (LLOD) to confirm cure post-treatment in near-patient technologies. Determining a LLOD at virologic failure aids in increasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Jake R., Savinkina, Alexandra, Pires dos Santos, Ana Gabriela, Xue, Zhenyi, Shilton, Sonjelle, Linas, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932931/
https://www.ncbi.nlm.nih.gov/pubmed/33590445
http://dx.doi.org/10.1007/s12325-021-01647-4
_version_ 1783660517317935104
author Morgan, Jake R.
Savinkina, Alexandra
Pires dos Santos, Ana Gabriela
Xue, Zhenyi
Shilton, Sonjelle
Linas, Benjamin
author_facet Morgan, Jake R.
Savinkina, Alexandra
Pires dos Santos, Ana Gabriela
Xue, Zhenyi
Shilton, Sonjelle
Linas, Benjamin
author_sort Morgan, Jake R.
collection PubMed
description INTRODUCTION: One of the remaining barriers to reaching WHO elimination targets of achieving global hepatitis C (HCV) cure is a lack of an established lower limit of detection (LLOD) to confirm cure post-treatment in near-patient technologies. Determining a LLOD at virologic failure aids in increasing testing feasibility through point-of-care assays in resource-limited settings. METHODS: We described the level of viremia in 69 patients experiencing virologic failure across 20 clinical trials (ENDURANCE-1, ENDURANCE-2, ENDURANCE-3, ENDURANCE-4, ENDURANCE 5–6, MAGELLAN-1, MAGELLAN-2, EXPEDITION-1, EXPEDITION-2, EXPEDITION-3, EXPEDITION-4, EXPEDITION-5, EXPEDITION-8, SURVEYOR-1, SURVEYOR-2, VOYAGE-1, VOYAGE-2, CERTAIN-1, CERTAIN-2 and APRI). These findings were categorized as on-treatment, post-treatment week (PTW) 4 or PTW12 failures. RESULTS: The mean HCV RNA level at baseline in the overall population of 5033 patients was 4,193,712 IU/ml ± 5,955,028 (6.2 log(10) IU/ml ± 0.8) compared to 9,585,957 IU/ml ± 8,247,669 (6.8 log(10) IU/ml ± 0.5) in 69 patients experiencing virologic failure by PTW12. The mean HCV RNA level at the time of virologic failure for all patients was 6,004,980 IU/ml ± 7,077,728 (6.4 log(10) IU/ml ± 0.7). Twenty patients had on-treatment virologic failure with a mean HCV RNA level at the time of failure of 9,136,360 IU/ml ± 8,572,113 (6.7 log(10) IU/ml ± 0.7), 36 patients had relapsed by PTW4 with a mean HCV RNA level at the time of relapse of 4,131,344 IU/ml ± 5,246,954 (6.3 log(10) IU/ml ± 0.6), and 13 patients, who experienced relapse between PTW4 and PTW12, had a mean HCV RNA at relapse of 6,376,003 IU/ml ± 7,758,968 (6.3 log(10) IU/ml ± 1.0). CONCLUSIONS: At PTW12, 100% of virologic failures had an HCV RNA > 3.0 log(10) IU/ml. The data are encouraging that with a LLOD of 3.0 log(10) IU/ml, a point-of-care test could identify all treatment failures accurately; larger studies, including real-world data, are needed to confirm these findings.
format Online
Article
Text
id pubmed-7932931
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-79329312021-03-19 HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients Morgan, Jake R. Savinkina, Alexandra Pires dos Santos, Ana Gabriela Xue, Zhenyi Shilton, Sonjelle Linas, Benjamin Adv Ther Original Research INTRODUCTION: One of the remaining barriers to reaching WHO elimination targets of achieving global hepatitis C (HCV) cure is a lack of an established lower limit of detection (LLOD) to confirm cure post-treatment in near-patient technologies. Determining a LLOD at virologic failure aids in increasing testing feasibility through point-of-care assays in resource-limited settings. METHODS: We described the level of viremia in 69 patients experiencing virologic failure across 20 clinical trials (ENDURANCE-1, ENDURANCE-2, ENDURANCE-3, ENDURANCE-4, ENDURANCE 5–6, MAGELLAN-1, MAGELLAN-2, EXPEDITION-1, EXPEDITION-2, EXPEDITION-3, EXPEDITION-4, EXPEDITION-5, EXPEDITION-8, SURVEYOR-1, SURVEYOR-2, VOYAGE-1, VOYAGE-2, CERTAIN-1, CERTAIN-2 and APRI). These findings were categorized as on-treatment, post-treatment week (PTW) 4 or PTW12 failures. RESULTS: The mean HCV RNA level at baseline in the overall population of 5033 patients was 4,193,712 IU/ml ± 5,955,028 (6.2 log(10) IU/ml ± 0.8) compared to 9,585,957 IU/ml ± 8,247,669 (6.8 log(10) IU/ml ± 0.5) in 69 patients experiencing virologic failure by PTW12. The mean HCV RNA level at the time of virologic failure for all patients was 6,004,980 IU/ml ± 7,077,728 (6.4 log(10) IU/ml ± 0.7). Twenty patients had on-treatment virologic failure with a mean HCV RNA level at the time of failure of 9,136,360 IU/ml ± 8,572,113 (6.7 log(10) IU/ml ± 0.7), 36 patients had relapsed by PTW4 with a mean HCV RNA level at the time of relapse of 4,131,344 IU/ml ± 5,246,954 (6.3 log(10) IU/ml ± 0.6), and 13 patients, who experienced relapse between PTW4 and PTW12, had a mean HCV RNA at relapse of 6,376,003 IU/ml ± 7,758,968 (6.3 log(10) IU/ml ± 1.0). CONCLUSIONS: At PTW12, 100% of virologic failures had an HCV RNA > 3.0 log(10) IU/ml. The data are encouraging that with a LLOD of 3.0 log(10) IU/ml, a point-of-care test could identify all treatment failures accurately; larger studies, including real-world data, are needed to confirm these findings. Springer Healthcare 2021-02-15 2021 /pmc/articles/PMC7932931/ /pubmed/33590445 http://dx.doi.org/10.1007/s12325-021-01647-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Morgan, Jake R.
Savinkina, Alexandra
Pires dos Santos, Ana Gabriela
Xue, Zhenyi
Shilton, Sonjelle
Linas, Benjamin
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
title HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
title_full HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
title_fullStr HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
title_full_unstemmed HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
title_short HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
title_sort hcv viral load greater than 1000 iu/ml at time of virologic failure in direct-acting antiviral-treated patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932931/
https://www.ncbi.nlm.nih.gov/pubmed/33590445
http://dx.doi.org/10.1007/s12325-021-01647-4
work_keys_str_mv AT morganjaker hcvviralloadgreaterthan1000iumlattimeofvirologicfailureindirectactingantiviraltreatedpatients
AT savinkinaalexandra hcvviralloadgreaterthan1000iumlattimeofvirologicfailureindirectactingantiviraltreatedpatients
AT piresdossantosanagabriela hcvviralloadgreaterthan1000iumlattimeofvirologicfailureindirectactingantiviraltreatedpatients
AT xuezhenyi hcvviralloadgreaterthan1000iumlattimeofvirologicfailureindirectactingantiviraltreatedpatients
AT shiltonsonjelle hcvviralloadgreaterthan1000iumlattimeofvirologicfailureindirectactingantiviraltreatedpatients
AT linasbenjamin hcvviralloadgreaterthan1000iumlattimeofvirologicfailureindirectactingantiviraltreatedpatients